Keyphrases
Related Conditions
100%
Phosphodiesterase Inhibitors
100%
Neuropeptides
100%
Blood-brain Barrier
100%
Immunopathology
100%
Neuropsychiatric
100%
Blood-brain
100%
Pituitary Adenylate Cyclase-activating Polypeptide (PACAP)
83%
Central Nervous System
66%
Vasoactive Intestinal Peptide
66%
Cyclic Adenosine Monophosphate (cAMP)
50%
Chronic Fatigue Syndrome
33%
Etiology
33%
Parkinson's Disease
33%
Multiple Sclerosis
33%
Autoimmunity
33%
Amyotrophic Lateral Sclerosis
33%
Virchow-Robin Spaces
33%
Phosphodiesterase
33%
Anti-neuroinflammation
33%
Neurodegenerative Processes
33%
Hypoxia
16%
Therapeutic Benefits
16%
Detrimental Effects
16%
Immune Function
16%
Pathomechanism
16%
Neurotransmitters
16%
Blood Vessels
16%
Perfusion
16%
Autoimmune
16%
Experimental Autoimmune Encephalomyelitis
16%
Adenylate Cyclase
16%
Vasodilator
16%
Pathological Process
16%
Functional Integrity
16%
Symptomatology
16%
Immunological Homeostasis
16%
Nociception
16%
Space Function
16%
Small Vessels
16%
PDE Inhibitors
16%
Regulatory T Cell(Treg)
16%
Enzyme Inhibitors
16%
Vasoactive Intestinal Peptide Receptor 1
16%
Autoimmune Pathology
16%
Enzyme Catalysis
16%
Barrier Integrity
16%
Neuropsychiatric Symptoms
16%
Autoimmune Event
16%
Leakiness
16%
Neuroscience
Neuropeptide
100%
Phosphodiesterase Inhibitor
100%
Blood Brain Barrier
100%
Vasoactive
100%
Hypophysis Adenylate Cyclase Activating Polypeptide
83%
Central Nervous System
66%
Vasoactive Intestinal Peptide
66%
Cyclic Adenosine Monophosphate
50%
Parkinson's Disease
33%
Multiple Sclerosis
33%
Chronic Fatigue Syndrome
33%
Amyotrophic Lateral Sclerosis
33%
Phosphodiesterase
33%
Neurodegenerative Process
33%
Receptor
16%
Autoimmune Disease
16%
T Cell
16%
Neurotransmitter
16%
Experimental Autoimmune Encephalomyelitis
16%
Adenylyl Cyclase
16%
Nociception
16%
Vasodilators
16%
Vasoactive Intestinal Polypeptide Receptor
16%
Neuropsychiatric Symptom
16%
Enzyme Inhibitor
16%
Pharmacology, Toxicology and Pharmaceutical Science
Phosphodiesterase Inhibitor
100%
Neuropeptide
100%
Blood-Brain Barrier
100%
Immunopathology
100%
Hypophysis Adenylate Cyclase Activating Polypeptide
83%
Vasoactive Intestinal Polypeptide
66%
Cyclic AMP
50%
Chronic Fatigue Syndrome
33%
Multiple Sclerosis
33%
Parkinson's Disease
33%
Amyotrophic Lateral Sclerosis
33%
Phosphodiesterase
33%
Hypoxia
16%
Receptor
16%
Autoimmune Disease
16%
Neurotransmitter
16%
Adenylate Cyclase
16%
Symptomatology
16%
Enzyme Inhibitor
16%
Experimental Autoimmune Encephalomyelitis
16%
Vasoactive Intestinal Polypeptide Receptor
16%
Immunology and Microbiology
Immunopathology
100%
Neuropeptide
100%
Blood Brain Barrier
100%
Vasoactive Intestinal Peptide
83%
Pituitary Adenylate Cyclase-Activating Polypeptide
83%
Central Nervous System
66%
Autoimmunity
66%
Chronic Fatigue Syndrome
33%
Regulatory T Cell
33%
Multiple Sclerosis
33%
Homeostasis
16%
Autoimmune Disease
16%
Peptide Receptor
16%
Precursor
16%
Perfusion
16%
Experimental Autoimmune Encephalomyelitis
16%
Blood Vessel
16%
Nociception
16%
Biochemistry, Genetics and Molecular Biology
Neuropeptide
100%
Phosphodiesterase
100%
Blood Brain Barrier
100%
Autoimmunity
83%
Vasoactive Intestinal Peptide
83%
Pituitary Adenylate Cyclase-Activating Polypeptide
83%
Cyclic Adenosine Monophosphate
50%
Regulatory T Cell
33%
Enzyme Inhibitor
16%
Homeostasis
16%
Peptide Receptor
16%
Precursor
16%
Animal Model
16%
Neurotransmitter
16%
Perfusion
16%
Nociception
16%
Adenylate Cyclase
16%
Enzyme Catalysis
16%